Group 1: Fund and Regulatory Developments - The second batch of floating fee funds has begun issuance, with three products set to launch on August 4, 2023, including a 3 billion yuan fundraising cap for one product [1] - The Hong Kong Stablecoin Regulation has officially come into effect on August 1, 2023, establishing a licensing system for fiat-backed stablecoin issuers to enhance regulatory oversight of virtual asset activities [1] Group 2: Market and IPO Updates - The Hong Kong Stock Exchange is proposing new rules allowing IPO applicants to choose between two distribution mechanisms, with the maximum percentage for public subscription being increased from 20% to 35% under one mechanism [2] - SensorTower forecasts that the global gaming market is expected to exceed $120 billion by 2028, with mobile game in-app purchase revenue projected to grow significantly [2] Group 3: Consumer and Entertainment Impact - Concerts, such as those by Jay Chou, have significantly boosted local consumption, with a reported ratio of 1 yuan spent on tickets generating 4.8 yuan in surrounding spending [3] - The performance of the concert industry is driving diverse consumer spending in urban areas, as evidenced by increased hotel bookings during major events [3] Group 4: Corporate Financial Performance - Apple CEO Tim Cook reported an $800 million loss due to tariffs, with an expected increase in costs of $1.1 billion for the current quarter [4] - Hanma Technology reported a 42.69% year-on-year increase in truck sales for July 2023, with production also seeing a significant rise [8] - Chipone Technology anticipates a revenue of approximately 584 million yuan for Q2 2023, marking a 49.90% quarter-on-quarter growth [11] Group 5: Strategic Partnerships and Acquisitions - Yabton Chemical has signed a 10-year strategic supply agreement with Jiangsu Hengrui Medicine to enhance collaboration in pharmaceutical intermediates and active pharmaceutical ingredients [9] - Apple has acquired approximately seven companies this year, focusing on various sectors, not limited to AI [4] Group 6: Real Estate and Land Acquisition - Hangzhou Garden has successfully bid 130 million yuan for land use rights in Yuhang District, planning to develop a smart ecological design R&D headquarters [10]

金融界消息 截至2025年8月1日收盘，甘李药业（603087）报收于60.99元，上涨5.34%，换手率5.14%， 成交量28.84万手，成交金额17.55亿元。 资金流向方面，今日主力资金净流入3409.28万元，占比成交额1.94%。其中，超大单净流入6145.27万 元、占成交额3.5%，大单净流出2736.00万元、占成交额1.56%，中单净流出流出3790.35万元、占成交 额2.16%，小单净流入381.07万元、占成交额0.22%。 天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次，知识 产权方面有商标信息190条，专利信息103条，此外企业还拥有行政许可449个。 来源：金融界 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2.15 ...

另外，控股子公司中国电子云深度应用大语言模型技术，结合多年政企数据治理实践经验，构建数据盘点智能体，以智能化、自动化之力，开启政企数据盘 点新模式。 龙虎榜知名游资 一、光伏 龙虎榜机构热股 今天机构龙虎榜上榜33只个股，净买入17只，净卖出16只。当日机构买入最多的个股前三位是：天府文旅（3日2.09亿）、昂利康（3日2.04亿）、深桑达A （1.04亿）。 | 上榜热股 | 实时涨跌幅 | 买/卖家数 | 机构 | | --- | --- | --- | --- | | 天府文旅 000558.SZ | +10.00% | 3/1 | +2 | | 3日 | | | | | 昂利康 002940.SZ | +10.00% | 4/2 | +2 | | 3日 | | | | 深桑达A 龙虎榜显示4家机构净买入1.04亿。 公司大力发展数据要素业务，推出云数一体可信数据空间产品，参与国家数据基础设施试点项目，并与智谱AI等头部企业合作推进AI平台落地。 7月31日，公司发布业绩预告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为17亿元–19.6亿元，比上年同期增长38.65%–59 ...

天眼查商业履历信息显示，博瑞生物医药(苏州)股份有限公司，成立于2001年，位于苏州市，是一家以 从事医药制造业为主的企业。企业注册资本42246.505万人民币，实缴资本22062.4827万人民币。公司法 定代表人为袁建栋。 通过天眼查大数据分析，博瑞生物医药(苏州)股份有限公司共对外投资了38家企业，参与招投标项目49 次，知识产权方面有商标信息121条，专利信息178条，此外企业还拥有行政许可37个。 来源：金融界 金融界消息 截至2025年8月1日收盘，博瑞医药（688166）报收于99.25元，上涨1.5%，换手率3.02%， 成交量12.75万手，成交金额12.69亿元。 资金流向方面，今日主力资金净流入2625.10万元，占比成交额2.07%。其中，超大单净流入2555.99万 元、占成交额2.01%，大单净流入69.11万元、占成交额0.05%，中单净流出流出5191.61万元、占成交额 4.09%，小单净流入2566.51万元、占成交额2.02%。 博瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比减少26.81%，归属净利 润1295.98万元，同比减少79. ...

金融界消息 截至2025年8月1日收盘，同仁堂（600085）报收于36.78元，上涨2.2%，换手率1.23%，成 交量16.91万手，成交金额6.22亿元。 天眼查商业履历信息显示，北京同仁堂股份有限公司，成立于1997年，位于北京市，是一家以从事医药 制造业为主的企业。企业注册资本137147.0262万人民币，实缴资本71930.85万人民币。公司法定代表人 为邸淑兵。 资金流向方面，今日主力资金净流入3864.77万元，占比成交额6.22%。其中，超大单净流入2937.82万 元、占成交额4.73%，大单净流入926.95万元、占成交额1.49%，中单净流出流出2172.72万元、占成交 额3.49%，小单净流出1692.05万元、占成交额2.72%。 同仁堂最新一期业绩显示，截至2025一季报，公司营业总收入52.76亿元、同比增长0.16%，归属净利润 5.82亿元，同比增长1.10%，扣非净利润5.81亿元，同比增长1.66%，流动比率3.450、速动比率1.943、 资产负债率32.65%。 通过天眼查大数据分析，北京同仁堂股份有限公司共对外投资了19家企业，参与招投标项目297次，知 识产 ...

Group 1: Market Impact - Trump's new tariff measures have negatively impacted global stock markets, with European markets collectively dropping over 1% [2][5] - The average tariff level on global goods has increased, raising concerns about potential economic growth slowdown and inflation, overshadowing previous optimism in large tech stocks driven by AI [5][7] Group 2: Economic Analysis - Analysts indicate that a 15% tariff rate is a poor agreement for the EU, with Goldman Sachs projecting a GDP loss of approximately 0.4 percentage points for the Eurozone by the end of 2026 [4] - The agreement signifies a turning point in US-EU relations, potentially affecting trade dynamics for years to come, ending an 80-year trend of reducing transatlantic trade barriers [4] Group 3: Regional Market Performance - Asian markets also experienced collective declines, with specific indices such as the KOSPI200 down by 4.08% and the Hang Seng Index down by 0.95% [8][9][7] - A-shares saw slight declines, with the Shanghai Composite Index down by 0.37% and the Shenzhen Component down by 0.17% [9] Group 4: Sector Performance - The pharmaceutical sector showed strength, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical up by 20% [14] - The photovoltaic sector rebounded, with stocks like Jiejia Weichuang and Shuangliang Energy hitting the daily limit up [15] Group 5: Company-Specific Developments - InnoScience's stock surged over 60% after being listed as a partner on NVIDIA's website, although the collaboration is still in the testing phase without substantial orders yet [17] - InnoScience's stock closed at HK$59.15, reflecting a 34.43% increase, with a trading volume of 64.21 million shares [18]

通过天眼查大数据分析，浙江新和成股份有限公司共对外投资了23家企业，参与招投标项目675次，知 识产权方面有商标信息366条，专利信息726条，此外企业还拥有行政许可110个。 新和成最新一期业绩显示，截至2025一季报，公司营业总收入54.40亿元、同比增长20.91%，归属净利 润18.80亿元，同比增长116.18%，扣非净利润18.80亿元，同比增长119.22%，流动比率2.610、速动比率 1.988、资产负债率29.74%。 金融界消息 截至2025年8月1日收盘，新 和 成（002001）报收于22.25元，下跌0.67%，换手率1.01%， 成交量30.65万手，成交金额6.90亿元。 天眼查商业履历信息显示，浙江新和成股份有限公司，成立于1999年，位于绍兴市，是一家以从事医药 制造业为主的企业。企业注册资本307342.168万人民币，实缴资本307342.168万人民币。公司法定代表 人为胡柏藩。 资金流向方面，今日主力资金净流入6417.59万元，占比成交额9.31%。其中，超大单净流入3721.99万 元、占成交额5.4%，大单净流入2695.59万元、占成交额3.91%，中单净流 ...

8月1日，Wind数据显示，A股市场共计49只个股涨停。其中燃气股胜通能源收获3连板；医药板块多股 连板，奇正藏药3连板，贵州百灵、昂利康、汉商集团2连板。一图速览今日连板股>> 连板股追踪丨A股今日共49只个股涨停 医药板块多股连板 ...

Group 1: Utilities - Recommended stock: Su Yan Jing Shen (603299.SH) due to its stable cash flow from traditional salt and salt chemical businesses, and the potential growth from gas storage projects [3][4] - The company is expected to enter a performance release period with the first phase of the gas storage project nearing production [4] Group 2: Pharmaceuticals - Recommended stock: Ang Li Kang (002940.SZ) as the impact of centralized procurement is gradually clearing, and new products are expected to drive revenue growth [4] - The introduction of ALK-N001, a promising anti-tumor candidate, is anticipated to enhance the company's innovation capabilities [4] Group 3: Media - Recommended stock: Alibaba-W (09988.HK) with a focus on the stabilization of traditional e-commerce and the potential for growth in the instant retail sector [5] - Alibaba Cloud's leading position in the domestic market and continuous revenue growth are highlighted [5] Group 4: Electronics - Recommended stock: Zhong Wei Company (688012.SH) due to its robust order backlog and continuous revenue growth driven by new product launches [6] Group 5: Non-Banking Financials - Recommended stock: China Life (601628.SH) for its excellent asset-liability matching and early transformation in dividend insurance sales [8] - The company is expected to release significant solvency capacity following asset reclassification [8] Group 6: Automotive - Recommended stock: Li Auto (02015.HK) as the company is positioned to leverage its strategic foresight and adaptability in the evolving automotive landscape [9] - The i-series is expected to maintain strong sales momentum, with the first model projected to achieve over 5,000 monthly sales [9] Group 7: Transportation - Recommended stock: YTO Express (600233.SH) with a leading growth rate in business volume, benefiting from the "anti-involution" trend in the industry [10] Group 8: Agriculture - Recommended stock: De Kang Agriculture (02419.HK) as it is positioned at a pivotal point in the agricultural sector, leveraging technology and innovative models for growth [12] - The company's platform strategy is expected to extend into other agricultural segments, enhancing its market presence [12] Group 9: Metals and New Materials - Recommended stock: Luoyang Molybdenum (603993.SH) with a strong performance in the first quarter, exceeding expectations [14] Group 10: North Exchange - Recommended stock: Yuan Hang Precision (833914.BJ) as a leading player in the domestic nickel-based conductor materials sector, benefiting from stable demand across multiple industries [14][15]

Core Viewpoint - The valuation of Nohow Health has been significantly reduced by multiple public funds, with Dachen Fund recently announcing a valuation of HKD 0.55 per share, marking the lowest valuation to date [1][3]. Valuation Adjustments - Dachen Fund's valuation of Nohow Health has been adjusted multiple times since its suspension in March 2024, dropping from HKD 14.14 per share to HKD 0.55 per share, representing a decline of over 96% [3][5]. - Other public funds, including Baoying, Penghua, and Bosera, have also reduced their valuations of Nohow Health, with Bosera maintaining a valuation of HKD 3.33 per share, which is still above HKD 2 per share [3][6]. Market Context - Nohow Health was once a leading stock in the Hong Kong market for cancer screening, with a market capitalization exceeding HKD 40 billion [5]. - The company has faced scrutiny over financial fraud allegations, leading to its suspension and inability to disclose timely financial reports [5][6]. Fund Management Perspective - The adjustments in valuation by fund managers aim to ensure the fairness and accuracy of fund net values, protecting investor interests [4][5]. - Continuous downward adjustments reflect a pessimistic outlook on Nohow Health's prospects for resumption of trading and heightened market vigilance regarding potential risks [6].